Abstract
Adenosine deaminase (ADA) deficiency was the first known cause of primary immunodeficiency. Over the past 25 years the basis for immune deficiency has largely been established. Now it appears that ADA deficiency may also cause hepatic toxicity, raising new questions about its pathogenesis. The ADA gene has been sequenced and the ADA three-dimensional structure solved. The relationship between genotype and phenotype is being analysed, and ADA deficiency has become a focus for novel approaches to enzyme replacement and gene therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Arredondo-Vega FX, Santisteban I, Kelly S, et al (1994) Correct splicing despite a G→A mutation at the invariant first nucleotide of a 5′ splice site: a possible basis for disparate clinical phenotypes in siblings with adenosine deaminase (ADA) deficiency. Am J Hum Genet 54: 820–830.
Benveniste P, Cohen A (1995) p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency. Proc Natl Acad Sci USA 92: 8373–8377.
Blaese RM, Culver KW, Miller AD, et al (1995) T lymphocyte-directed gene therapy for ADASCID: initial trial results after 4 years. Science 270: 475–480.
Bollinger ME, Arredondo-Vega FX, Santisteban I, et al (1996) Hepatic dysfunction as a complication of adenosine deaminase (ADA) deficiency. N Engl J Med 334: 1367–1371.
Bordignon C, Notarangelo L, Nobili N, et al (1995) Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270: 470–475.
Carson DA, Kaye J, Matsumoto S, et al (1979) Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. Proc Natl Acad Sci USA 76: 2430–2433.
Chaffee S, Mary A, Stiehm ER, et al (1992) IgG antibody response to polyethylene glycol-modified adenosine deaminase (PEG-ADA) in patients with adenosine deaminase deficiency. J Clin Invest 89: 1643–1651.
Chang ZY, Nygaard P, Chinault AC, et al (1991) Deduced amino acid sequence of Escherichia coli adenosine deaminase reveals evolutionarily conserved amino acid residues: implications for catalytic function. Biochemistry 30: 2273–2280.
Cohen A, Hirschhorn R, Horowitz SD, et al (1978) Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci USA 75: 472–475.
Coleman MS, Donofrio J, Hutton JJ, et al (1978) Identification and quantitation of adenine deoxynucleotides in erythrocytes of a patient with adenosine deaminase deficiency and severe combined immunodeficiency. J Biol Chem 253: 1619–1626.
Gao X, Knudsen TB, Ibrahim MM, et al (1995) Bcl-2 relieves deoxyadenylate stress and suppresses apoptosis in pre-B leukemia cells. Cell Death and Differentiation 2: 69–78.
Giblett ER, Anderson JE, Cohen F, et al (1972) Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2: 1067–1069.
Giblett ER, Ammann AJ, Wara DW, et al (1975) Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1: 1010.
Greenberg ML, Chaffee S, Hershfield MS (1989) Basic for resistance to 3-deazaaristeromycin, an inhibitor of S-adenosylhomocysteine hydrolase, in human B-lymphoblasts. J Biol Chem 264: 795–803.
Hershfield MS, Kredich NM (1980) Resistance of an adenosine kinase-deficient human lymphoblastoid cell line to effects of deoxyadenosine on growth, S-adenosylhomocysteine hydrolase inactivation, and dATP accumulation. Proc Natl Acad Sci USA 77: 4292–4296.
Hershfield MS (1979) Apparent suicide inactivation of human lymphoblast S-adenosylhomocysteine hydrolase by 2′-deoxyadenosine and adenine arabinoside. A basis for direct toxic effects of analogs of adenosine. J Biol Chem 254: 22–25.
Hershfield MS (1995a) PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin Immunol Immunopathol 76: S228–S232.
Hershfield MS (1995b) PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. Hum Mutat 5: 107–112.
Hershfield MS, Mitchell BS (1997) Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th edn. CD-ROM version. New York: McGraw-Hill, in press.
Hershfield MS, Kredich NM, Ownby DR, et al (1979) In vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2′-deoxyadenosine in adenosine deaminase-deficient patients. J Clin Invest 63: 807–811.
Hershfield MS, Kredich NM, Koller CA, et al (1983) S-Adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2′-deoxycoformycin alone and in combination with 9-β-D-arabinofuranosyladenine. Cancer Res 43: 3451–3458.
Hershfield MS, Kurtzberg J, Moore JO, et al (1984) Conversion of a stem cell leukemia from T-lymphoid to a myeloid phenotype by the adenosine deaminase inhibitor 2′-deoxycoformycin. Proc Natl Acad Sci USA 81: 253–257.
Hershfield MS, Buckley RH, Greenberg ML, et al (1987) Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 316: 589–596.
Hershfield MS, Chaffee S, Sorensen RU (1993) Enzyme replacement therapy with PEG-ADA in adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy. Pediatr Res 33(supplement): S42–S48.
Hirschhorn R (1995) Adenosine deaminase deficiency: molecular basis and recent developments. Clin Immunol Immunopathol 76: S219–S227.
Hirschhorn R, Tzall S, Ellenbogen A (1990) Hot spot mutations in adenosine deaminase deficiency. Proc Natl Acad Sci USA 87: 6171–6175.
Hirschhorn R, Yang DR, Israni A, et al (1994) Somatic mosaicism for a newly identified splice-site mutation in a patient with adenosine deaminase-deficient immunodeficiency and spontaneous clinical recovery. Am J Hum Genet 55: 59–68.
Hirschhorn R, Yang DR, Puck JM, et al (1996) Spontaneous reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency. Nature Genet 13: 290–295.
Hoogerbrugge PM, van Beusechem VW, Fischer A, et al (1996) Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther 3: 179–183.
Kizaki H, Shimada H, Ohsaka F, et al (1988) Adenosine, deoxyadenosine, and deoxyguanosine induce DNA cleavage in mouse thymocytes. J Immunol 141: 1652–1657.
Kohn DB, Weinberg KI, Nolta JA, et al (1995) Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nature Med 1: 1017–1023.
Kredich NM, Hershfield MS (1979) S-Adenosylhomocysteine toxicity in normal and adenosine kinase-deficient lymphoblasts of human origin. Proc Natl Acad Sci USA 76: 2450–2454.
Kredich NM, Martin DW Jr (1977) Role of S-adenosylhomocysteine in adenosine-mediated toxicity in cultured mouse T-lymphoma cells. Cell 12: 931–938.
Liu X, Kim CN, Yang J, et al (1996) Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86: 147–157.
Migchielsen AAJ, Breuer ML, van Roon MA, et al (1995) Adenosine deaminase-deficient mice die perinatally, exhibiting liver-cell degeneration, small intestinal cell death and lung atelectasis. Nature Genet 10: 279–287.
Nyhan WS (1997) The recognition of Lesch-Nyhan syndrome as an inborn error of purine metabolism. J Inher Metab Dis 20: 171–178.
Orkin S, Motulsky A (1995) Report and recommendations of the panel to assess the NIH investment in research on gene therapy. World Wide Web http://www.nih.gov/news/panelrep.html.
Ozsahin H, Arredondo-Vega FX, Santisteban I, et al (1997) Adenosine deaminase deficiency in adults. Blood, in press.
Polmar SH, Stern RC, Schwartz AL, et al (1976) Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency. N Engl J Med 295: 1337–1343.
Renshaw J, Harrap KR (1986) In vivo inhibition of mouse liver methyltransferase enzymes following treatment with 2′-deoxycoformycin and 2′-deoxyadenosine. Adv Exp Med Biol 195B: 673–675.
Santisteban I, Arredondo-Vega FX, Kelly S, et al (1993) Novel splicing, missense, and deletion mutations in 7 adenosine deaminase deficient patients with late/delayed onset of combined immunodeficiency disease: contribution of genotype to phenotype. J Clin Invest 92: 2291–2302.
Seto S, Carrera CJ, Kubota M, et al (1985) Mechanism of deoxyadenosine and 2-chlorodeoxy-adenosine toxicity to nondividing human lymphocytes. J Clin Invest 75: 377–383.
Shovlin CL, Hughes JMB, Simmonds HA, et al (1993) Adult presentation of adenosine deaminase deficiency. Lancet 341: 1471.
Shovlin CL, Simmonds HA, Fairbanks L, et al (1994) Adult onset immunodeficiency caused by inherited adenosine deaminase deficiency. J Immunol 153: 2331–2339.
Stockler S, Isbrandt D, Hanefeld F, et al (1996) Guanidinoacetate methyltransferase deficiency: the first inborn error of creatine metabolism in man. Am J Hum Genet 58: 914–922.
Ullman B, Gudas LJ, Cohen A, et al (1978) Deoxyadenosine metabolism and cytotoxicity in cultured mouse T lymphoma cells. A model for immunodeficiency disease. Cell 14: 365–375.
Ullman B, Clift SM, Gudas LJ, et al (1980) Alterations in deoxyribonucleotide metabolism in cultured cells with ribonucleotide reductase activities refractory to feedback inhibition by 2′-deoxyadenosine triphosphate. J Biol Chem 255: 8308.
Wakamiya M, Blackburn MR, Jurecic R, et al (1995) Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice. Proc Natl Acad Sci USA 92: 3673–3677.
Weinberg K, Hershfield MS, Bastian J, et al (1993) T lymphocyte ontogeny in adenosine deaminase deficient severe combined immune deficiency following treatment with polyethylene glycol modified adenosine deaminase. J Clin Invest 92: 596–602.
Wiginton DA, Kaplan DJ, States JC, et al (1986) Complete sequence and structure of the gene for human adenosine deaminase. Biochemistry 25: 8234–8244.
Wilson DK, Rudolph FB, Quiocho FA (1991) Atomic structure of adenosine deaminase complexed with a transition-state analog: understanding catalysis and immunodeficiency mutations. Science 252: 1278–1284.
Wolos JA, Frondorf KA, Davis GF, et al (1993a) Selective inhibition of T cell activation by an inhibitor of S-adenosyl-L-homocysteine hydrolase. J Immunol 150: 3264–3273.
Wolos JA, Frondorf KA, Esser RE (1993b) Immunosuppression mediated by an inhibitor of S-adenosyl-L-homocysteine hydrolase. J Immunol 151: 526–534.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hershfield, M.S., Arredondo-Vega, F.X. & Santisteban, I. Clinical expression, genetics and therapy of adenosine deaminase (ADA) deficiency. J Inherit Metab Dis 20, 179–185 (1997). https://doi.org/10.1023/A:1005300621350
Issue Date:
DOI: https://doi.org/10.1023/A:1005300621350